Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations

BACKGROUND: Conventional therapeutic agents are largely unsatisfactory into the treatment of malignant melanoma. Recently, an innovative approach based on inhibitors of the mutated BRAF gene (which represents the most prevalent alteration in melanoma patients) appears very promising from the clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Gentilcore, Giusy, Madonna, Gabriele, Mozzillo, Nicola, Ribas, Antoni, Cossu, Antonio, Palmieri, Giuseppe, Ascierto, Paolo A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586362/
https://www.ncbi.nlm.nih.gov/pubmed/23317446
http://dx.doi.org/10.1186/1471-2407-13-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586362/
https://www.ncbi.nlm.nih.gov/pubmed/23317446
http://dx.doi.org/10.1186/1471-2407-13-17

Ejemplares similares